Ocular Therapeutix (OCUL) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 0.3% versus a loss of 37.2%. Over five years, PAHC leads with a +73.0% price change compared with -35.4% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.65 billion vs $1.52 billion), about 1.1 times the size.
Phibro Animal Health pays a dividend yielding 1.28%, while Ocular Therapeutix does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | PAHC |
|---|---|---|
| Share price | $7.51 | $37.40 |
| Market cap | $1.65B | $1.52B |
| 1-day change | +3.87% | -0.85% |
| YTD return | -40.44% | +0.96% |
| 1-year return | -37.24% | +0.27% |
| 5-year return | -35.39% | +73.03% |
| P/E ratio (TTM) | — | 15.39 |
| Forward P/E | — | 9.73 |
| EPS (TTM) | $-1.40 | $2.43 |
| Dividend yield | 0.00% | 1.28% |
| Annual dividend | $0.00 | $0.48 |
| 52-week high | $16.44 | $60.08 |
| 52-week low | $6.23 | $28.25 |
| Distance from 52-week high | -54.32% | -37.75% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +260.72% | +17.65% |
| Average volume | 2.78M | 235.16K |
| Shares outstanding | 219.62M | 21.11M |
| Employees | 325 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAHC has outperformed OCUL by 37.5 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
OCUL vs PAHC FAQ
Which is bigger, Ocular Therapeutix or Phibro Animal Health?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.65B compared with $1.52B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, OCUL or PAHC?
PAHC returned +0.27% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Ocular Therapeutix or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.28%, while Ocular Therapeutix does not currently pay a regular dividend.
Are Ocular Therapeutix and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.